Laura Cristina Gironi, Giovanni Damiani, Elisa Zavattaro, Alessia Pacifico, Pierachille Santus, Paolo Daniele Maria Pigatto, Ottavio Cremona, Paola Savoia
Dermatologic therapy 2021 JanTetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential antiviral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. A multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC was performed. About 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]) were enrolled. During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms. © 2020 Wiley Periodicals LLC.
Laura Cristina Gironi, Giovanni Damiani, Elisa Zavattaro, Alessia Pacifico, Pierachille Santus, Paolo Daniele Maria Pigatto, Ottavio Cremona, Paola Savoia. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses. Dermatologic therapy. 2021 Jan;34(1):e14694
PMID: 33354849
View Full Text